Nanoliposomal Bcl-xL proteolysis-targeting chimera enhances anti-cancer effects on cervical and breast cancer without on-target toxicities

J Zhang, B Zhang, C Pu, J Cui, K Huang… - … Composites and Hybrid …, 2023 - Springer
Bcl-xL is a well-characterized target gene of cancer. DT2216, a selective proteolysis-
targeting chimera (PROTAC) has been developed for targeting Bcl-xL without causing …

Hybrid nanoparticles coated with hyaluronic acid lipoid for targeted co-delivery of paclitaxel and curcumin to synergistically eliminate breast cancer stem cells

Z Yang, N Sun, R Cheng, C Zhao, J Liu… - Journal of Materials …, 2017 - pubs.rsc.org
Conventional chemotherapy drugs such as paclitaxel (PTX) can effectively inhibit tumor
growth by killing the majority of the proliferating cancer cells; however, it also results in multi …

Lysosome-independent intracellular drug/gene codelivery by lipoprotein-derived nanovector for synergistic apoptosis-inducing cancer-targeted therapy

W Wang, K Chen, Y Su, J Zhang, M Li… - Biomacromolecules, 2018 - ACS Publications
In this paper, reconstituted high-density lipoprotein (rHDL), a lipoprotein-derived nanovector,
was constructed for codelivery of paclitaxel (PTX) and wild-type p53 gene (p53). The particle …

Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis

C Chen, Q Guo, H Fu, J Yu, Y Sun, J Zhang, Y Duan - Biomaterials, 2021 - Elsevier
Abstract PD-L1/PD-1 blockade therapy shows durable responses to triple-negative breast
cancer (TNBC), but the response rate is low. CD155 promotes tumor metastasis intrinsically …

Synergistic Anticancer Response via Docetaxel-and Oleanolic Acid-Loaded Albumin/Poly (lactide) Nanoparticles in Triple-Negative Breast Cancer

S Das, M Paul, B Ghosh, S Biswas - ACS Applied Nano Materials, 2023 - ACS Publications
Triple-negative breast cancer (TNBC) is the most aggressive form of breast cancer with a
poor prognosis. A highly effective chemotherapeutic treatment strategy is yet to be …

Enzyme-sensitive nanoparticles, smart TAT and cetuximab conjugated immunoliposomes to overcome multidrug resistance in breast cancer cells

M Safaei, P Khosravian, SK Sheykhshabani… - Toxicology and Applied …, 2022 - Elsevier
Due to recent advances in the field of small molecule-based drugs, designing an efficient
siRNA delivery system seems essential. Here, modified sets of lipids conjugated with cell …

[HTML][HTML] Natural polyphenol-loaded cross-linked lipoic acid vesicles treat triple-negative breast cancer by cancer cell killing and metastasis inhibition

P Jing, H Luo, J Tan, C Liao, S Zhang - Materials & Design, 2023 - Elsevier
The high incidence of metastases remains a major hurdle for triple negative breast cancer
(TNBC) treatment. Herein, we developed a fairly safe anticancer nanodrug for TNBC …

Codelivery of Que and BCL-2 siRNA with Lipid–Copolymer Hybrid Nanocomplexes for Efficient Tumor Regression

K Li, X Cai, Y Fan, M Jin, Y Xie, Z Jing… - ACS Biomaterials …, 2023 - ACS Publications
The efficacy of chemotherapy is often reduced due to the chemotherapy resistance of tumor
cells, which is usually caused by abnormal gene overexpression. Herein, multifunctional …

In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis

Y Li, Y Xiao, HP Lin, D Reichel, Y Bae, EY Lee, Y Jiang… - Biomaterials, 2019 - Elsevier
Cancer stem cells (CSCs) play pivotal roles in cancer metastasis, and strategies targeting
cancer stemness may greatly reduce cancer metastasis and improve patients' survival. The …

Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel-and cetuximab-conjugated nanodiamond nanocomposite

WS Liao, Y Ho, YW Lin, EN Raj, KK Liu, C Chen… - Acta biomaterialia, 2019 - Elsevier
Breast cancer is the most common malignancy and a leading cause of cancer-related
mortality among women worldwide. Triple-negative breast cancer (TNBC) is characterized …